Лориста Н

Quick links

Choose a section

Quick links to important sections

Advertisements

Лориста Н

Selected form

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Лориста Н

What is Лориста Н?

Лориста Н is a combination prescription medication used primarily in the management of cardiovascular health. It belongs to a class of drugs that combine two different types of active ingredients to achieve a synergistic effect on blood pressure regulation.

Components and Mechanism

The medication consists of two primary active substances:

  • Losartan potassium: An angiotensin II receptor blocker (ARB). It works by blocking the action of certain natural substances that tighten the blood vessels, allowing the blood vessels to relax and widen.
  • Hydrochlorothiazide: A thiazide diuretic, often referred to as a "water pill." It helps the body eliminate excess salt and water through urine, which reduces the overall volume of fluid circulating through the blood vessels.

Purpose of the Combination

By combining an ARB with a diuretic, Лориста Н addresses blood pressure management through two distinct physiological pathways. This dual approach is often utilized when a single medication is not sufficient to reach target levels. The goal of this combined therapy is to facilitate smoother blood flow and reduce the workload on the heart and vascular system.

Appearance and Form

Лориста Н is typically produced in tablet form for oral administration. The tablets are film-coated, which helps protect the active ingredients and facilitates easier swallowing. As a combination product, it is available in specific fixed-dose strengths, where the ratio of losartan to hydrochlorothiazide is pre-determined to ensure consistent therapeutic delivery.

Advertisements

What side effects are possible with Лориста Н?

Possible Side Effects and Safety Information

The safety profile of Losartan / Hydrochlorothiazide (Лориста Н) is formally documented by government regulatory agencies, classifying potential adverse reactions based on their observed frequency and the body systems affected.

Documented Adverse Reactions

The most frequently reported adverse reactions are classified as common in official prescribing information, primarily affecting the nervous and musculoskeletal systems. These commonly documented effects include dizziness, headache, and fatigue/asthenia.

Less frequently reported, or uncommon, reactions encompass events such as palpitations, insomnia, and certain gastrointestinal disturbances. The product's safety information also documents metabolic effects, notably changes in electrolyte levels (e.g., hypokalemia and hyperuricemia), driven by the hydrochlorothiazide component.

Serious Safety Considerations

Official regulatory documents list rare but clinically significant serious adverse reactions. These include Angioedema, a severe hypersensitivity reaction involving swelling of the face, lips, and throat, and other rare systemic reactions. Additionally, the label documents the risk of Fetal Toxicity when used during the second and third trimesters of pregnancy, and an association between prolonged, cumulative use of Hydrochlorothiazide and the risk of Non-Melanoma Skin Cancer.

Population and Use-Related Constraints

The safety profile includes specific limitations for certain patient groups. The medication is contraindicated in individuals with severe renal impairment (creatinine clearance less than 30 mL/min) and severe hepatic impairment, as well as in patients who are pregnant (second and third trimesters). Time-related safety patterns note that effects such as low blood pressure and dizziness are more likely to occur upon treatment initiation or dose escalation.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of the combination medication Лориста Н (Losartan/Hydrochlorothiazide) can cause significant symptoms, primarily related to its blood pressure-lowering and diuretic effects. The most likely acute manifestation of an overdose is hypotension (abnormally low blood pressure) and tachycardia (rapid heart rate). Bradycardia (slow heart rate) may also occur due to vagal stimulation. The diuretic component, hydrochlorothiazide, may lead to excessive loss of fluids and electrolytes, resulting in dehydration and electrolyte imbalances such as hypokalemia (low potassium).

Signs of a potential overdose requiring immediate attention may include severe dizziness, lightheadedness, fainting, and unusual weakness. Electrolyte disturbances can manifest as muscle cramps, irregular heartbeat, or extreme thirst.

When to Seek Emergency Help

Immediately contact emergency medical services or a poison control center if you suspect an overdose. Do not wait for symptoms to worsen. The priority of care for an overdose is supportive treatment, primarily focusing on correcting severe hypotension and electrolyte imbalance.

Symptom Category Key Signs of Severe Overdose
Cardiovascular Severe dizziness, fainting, very low blood pressure
Electrolytes/Fluid Extreme thirst, muscle cramps, irregular or slow heartbeat
Consciousness Confusion, extreme drowsiness, unresponsiveness

Bring the medication container and as much information as possible about the amount taken to the medical facility. Since losartan is highly protein-bound, dialysis is generally ineffective in removing the drug or its active metabolite from the bloodstream.

Advertisements

Therapeutic Uses of Лориста Н

What Лориста Н Treats: Main Uses and Benefits

Лориста Н is commonly used for the continuous management of essential hypertension (chronic high blood pressure) in adults. This medication is applied across therapeutic domains where single-agent therapy may not be providing adequate support for stabilizing elevated systolic and diastolic blood pressure readings. The combination is indicated for the treatment of hypertension to lower blood pressure.

This combination supports achieving and maintaining blood pressure levels, which may assist with easing symptoms related to systemic imbalance and cardiovascular strain. The therapeutic areas for which it is relevant are commonly used to help with chronic high blood pressure, assisting with managing blood pressure levels in patients with Left Ventricular Hypertrophy (LVH), and helping reduce the risk of cardiovascular events. The treatment is commonly used to help manage the risk of organ-specific functional stress.

“This type of dual-agent therapy is relevant in clinical settings that involve heightened systemic burden, where continuous support for blood pressure stabilization may be appropriate.”

This supports the patient by contributing to easing the impact of the condition, which may help reduce the likelihood of future strokes and heart attacks. The fixed-dose formulation also assists with maintaining functional stability by offering a convenient single-pill option for patients who may benefit from dual management.

Quick Fact: Support for Cardiovascular Strain The medication helps address symptoms related to heightened physiological activity and supports the patient during episodes of heightened discomfort related to systemic imbalance.

Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

The eligibility profile for Лориста Н (Losartan/Hydrochlorothiazide) is defined by mandatory exclusions and population-specific restrictions documented in regulatory labeling. The medicine is primarily approved for adult patients with hypertension.

Eligibility Scope Status as per Regulatory Labeling
Populations Allowed Adults with essential hypertension.
Age-Related Not recommended for children/adolescents (<18 years); safety and effectiveness not established for the fixed combination.
Pregnancy Status Contraindicated during the second and third trimesters. Must be discontinued as soon as possible if pregnancy is detected.
Lactation Not recommended due to potential adverse effects on the nursing infant.

Absolute Contraindications formally prohibit use in patients with certain conditions:

  • Anuria (inability to produce urine).
  • Severe Renal Impairment (Creatinine Clearance le 30 mL/min).
  • Severe Hepatic Impairment, cholestasis, or biliary obstructive disorders.
  • Hypersensitivity to the components (Losartan, Hydrochlorothiazide) or sulfonamide-derived drugs.
  • Co-administration with aliskiren in patients with diabetes mellitus or renal impairment.

Use is also not recommended in patients with therapy-resistant electrolyte imbalances (e.g., severe hypokalaemia/hypercalcaemia) or symptomatic hyperuricaemia/gout. Use in adults who are volume-depleted or salt-depleted requires correction of the condition prior to administration.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Losartan/Hydrochlorothiazide (Лориста Н) through specific pharmacokinetic and pharmacodynamic mechanisms, leading to defined restrictions on co-administration.

Contraindicated and Restricted Combinations

Classification Interacting Entity Context and Effect
Contraindicated Aliskiren Forbidden in patients with Type 2 diabetes mellitus or moderate-to-severe renal impairment (GFR < 60 mL/min/1.73 m^2).
Restricted Potassium-Sparing Diuretics (e.g., Triamterene) Not generally recommended due to increased risk of hyperkalemia (high potassium levels).

Documented Pharmacokinetic and Pharmacodynamic Interactions

Certain substances can alter the concentration of the active drug components. Fluconazole, a known CYP2C9 inhibitor, increases the systemic exposure of Losartan while reducing the exposure of its active metabolite. Conversely, Phenobarbital can decrease the exposure of Losartan and its metabolite.

Lithium co-administration is associated with a reduction in its renal clearance, which can lead to increased serum Lithium concentrations and potential toxicity. Furthermore, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may diminish the antihypertensive effect and increase the risk of renal deterioration, particularly in volume-depleted patients.

Administration Timing Requirement

To ensure adequate absorption of the Hydrochlorothiazide component, the medicine must be administered 4 hours before or 4 to 6 hours after binding agents like Cholestyramine or Colestipol. Alcohol consumption is documented to potentiate the orthostatic hypotensive effect.

Advertisements

Mechanism of Action

Interrupting Angiotensin II Signaling at the AT1 Receptor

This domain covers the action of the Losartan component, which functions as a selective antagonist (blocker) of the Angiotensin II Type 1 (AT1 ) Receptor. This specific molecular mechanism interrupts the primary constricting signal from the Renin-Angiotensin-Aldosterone System (RAAS), consequently mediating the relaxation and widening of arterial smooth muscle and a decrease in Systemic Vascular Resistance (SVR).

Modulating Fluid Volume through Renal Salt Inhibition

This section addresses the physiological effect of Hydrochlorothiazide, which acts as a molecular inhibitor of the Sodium-Chloride Cotransporter (NCC) in the kidney's distal convoluted tubule. By blocking the reabsorption of sodium and chloride ions, this mechanism increases the osmotic pull of water into the urine, which is the biological cascade that mediates a decrease in Extracellular Fluid Volume (ECFV).

Mechanistic Synergy and Homeostatic Augmentation

The combined effect is achieved through complementary biological mechanisms: the volume reduction caused by Hydrochlorothiazide's action would normally trigger a counter-regulatory response from the RAAS. However, Losartan's receptor blockade mechanism prevents the activation of this compensatory pathway, thereby maximizing the physiological change by influencing both vascular resistance and fluid volume simultaneously.

Advertisements

Dosage and Administration Information

How to Use Лориста Н: Administration Guidelines

Лориста Н (Losartan/Hydrochlorothiazide) is an oral, film-coated tablet designed for the long-term management of high blood pressure. The medication is taken by mouth, and the frequency for administration is once daily. The tablet may be administered either with or without food. It must be swallowed whole with water and should not be crushed, broken, or chewed.


Dosing Regimens

The standard protocol involves starting use with the lowest available fixed-dose strength. The initial dose for most adults is 50 mg/12.5 mg (Losartan/HCTZ) once daily. If blood pressure remains uncontrolled, the dosage may be adjusted after approximately three weeks of therapy. The maximum daily dose is 100 mg/25 mg once daily.


Use-Context Constraints

Specific patient constraints apply to this medication. The combination product is not recommended for use in children and adolescents under 18 years of age. Furthermore, due to the combination's composition, it is generally not recommended for use in patients with severe renal impairment (typically defined as creatinine clearance leq 30 mL/min) or severe hepatic impairment. If a patient experiences volume or salt depletion, this condition must be corrected prior to administration of the medication to ensure proper usage.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence

Overview of Combination Therapy

Clinical research examining fixed-dose combinations of Losartan (an Angiotensin II Receptor Blocker, ARB) and Hydrochlorothiazide (HCTZ, a diuretic) has consistently supported their combined use in managing essential hypertension. Studies evaluate whether combining these agents provides a complementary mechanism of action, potentially achieving target blood pressure goals more effectively than either component used alone.

Efficacy and Target Attainment

Trials demonstrate that combination therapy may be associated with improved blood pressure (BP) control and increased rates of patients achieving BP targets compared to monotherapy. This benefit is often attributed to the ARB component inhibiting vasoconstriction while the diuretic component promotes fluid and sodium excretion, thereby reducing blood volume.

  • Losartan Role: Primarily examined for its effect on reducing systemic vascular resistance.
  • HCTZ Role: Primarily studied for its effect on reducing fluid volume and cardiac preload.

Clinical Findings Summary

Research has explored the efficacy and safety profile of this fixed-dose combination, with key findings focusing on dosage and demographic factors. In studies involving patients with moderate to severe hypertension, the use of Losartan/HCTZ was observed to be associated with mean reductions in both systolic and diastolic BP within the first few weeks of administration. Long-term observational studies are sometimes conducted to investigate cardiovascular outcomes in specific high-risk populations. The combination's use is supported by major clinical guidelines for patients whose BP is not adequately controlled by Losartan monotherapy.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Лориста Н (FAQ)


Q: How is Lorista H different from regular Lorista (without H)?

A: According to the official product information, Lorista H is a fixed-dose combination medication. It contains two active ingredients: the Angiotensin II Receptor Blocker (ARB) Losartan and the diuretic Hydrochlorothiazide (HCTZ). The primary difference from the standard Losartan monotherapy is the inclusion of this additional diuretic component.


Q: What does the letter 'H' mean in the name Lorista H?

A: The letter 'H' in the name of the drug stands for Hydrochlorothiazide (HCTZ), which is one of the two active ingredients. This component is a thiazide diuretic included to complement the blood pressure lowering effect of Losartan.


Q: How long after starting Lorista H can a full effect be expected?

A: Official documents indicate that the full therapeutic effect of this combination medication is typically reached gradually. The maximum blood pressure lowering effect may be observed within a period of three to six weeks after the treatment is started or the dosage is adjusted.


Q: Is Lorista H approved for people with diabetes?

A: The official product labeling states that the medication is contraindicated (forbidden) for use alongside Aliskiren, particularly in patients with Type 2 diabetes. Furthermore, the Hydrochlorothiazide component may impair glucose tolerance and cause elevated blood sugar levels. Patients with diabetes may require adjustment to the dosage of their anti-diabetic medications.


Q: What is the maximum duration of action of one Lorista H tablet?

A: This medication is designed for convenient once-daily administration. Official pharmacokinetic data indicates that the activity of the diuretic component, Hydrochlorothiazide, persists for up to 24 hours, which is the basis for its sustained effect.


Q: Can people who drive a car take Lorista H?

A: Official regulatory documents advise that side effects such as dizziness or drowsiness may occasionally occur while taking this medication. These effects are often noted when treatment is initiated or the dosage is increased. Such effects could potentially impair a person's ability to drive or operate complex machinery.


Q: Does Lorista H affect blood sugar levels?

A: The Hydrochlorothiazide component of the medication may have metabolic effects, including potentially impairing glucose tolerance, which can lead to hyperglycemia (high blood sugar). For this reason, official safety information suggests that patients with diabetes may require careful monitoring and possible dosage adjustment of their anti-diabetic medicines.


Q: Why does a dry cough sometimes occur when taking Lorista H?

A: The official prescribing information lists cough as a potential adverse reaction to the medication. This effect has been documented in clinical trials and is part of the established safety profile for Losartan/Hydrochlorothiazide.


Q: What to do if blood pressure does not decrease immediately after starting Lorista H?

A: Regulatory guidelines indicate that if blood pressure measurements remain uncontrolled, the dosage may be considered for adjustment. This adjustment is typically considered after approximately three weeks of therapy at the initial strength.


Q: Does the consumption of grapefruit juice affect the action of Lorista H?

A: Regulatory-linked health resources indicate that grapefruit juice may interfere with the metabolism of the Losartan component of the medication. Regulatory information notes that caution may be necessary regarding the consumption of grapefruit products.


Q: How is Lorista H described in official documents regarding target organ protection?

A: The official indications for this drug include reducing the risk of a cardiovascular event, specifically stroke, in certain patient populations. This indication applies to patients with high blood pressure who also have left ventricular hypertrophy (an enlargement of the heart muscle).


Q: Is regular use of Lorista H essential for the treatment to be effective?

A: The medication is intended for regular, once-daily use, as its effectiveness relies on maintaining consistent drug levels in the body. Official patient counseling documentation cautions that suddenly stopping the drug can lead to a rapid and potentially significant increase in blood pressure.


Q: Is it described in the instructions what to do if common side effects appear?

A: The medication instructions provide explicit steps for managing certain rare but serious side effects, such as immediately calling a healthcare provider and stopping the drug if symptoms like swelling of the face or vision changes occur. However, official regulatory text generally does not include patient self-management advice for common side effects like headache or fatigue.


Q: Is the process of switching to Lorista H from other medications described in official sources?

A: Official drug labeling provides instructions for initiating the fixed-dose combination in specific situations. For example, the regulatory text details the process for patients whose blood pressure is not adequately controlled when they are already taking Losartan monotherapy.


Q: Is it necessary to follow a special diet when being treated with Lorista H?

A: Regulatory documents note that the drug is part of a comprehensive cardiovascular risk management plan, which includes general advice on lifestyle and diet, such as limited sodium intake. Additionally, patients who are severely volume- or salt-depleted must have these conditions corrected before beginning therapy.


Q: Is there a connection between taking Lorista H and worsening vision?

A: Official safety information states that the medication may be associated with eye problems. Documented adverse reactions include transient blurred vision and other vision changes, as well as the rare, serious risk of acute angle-closure glaucoma.


Q: Can Lorista H be taken during flu or a cold?

A: While official documents do not comment on temporary illness itself, there are specific warnings regarding drug interactions. The co-administration of this medication with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), often found in over-the-counter cold and flu remedies, may diminish the blood pressure effect and increase the risk of kidney issues.


Q: Are there restrictions on taking Lorista H before surgery?

A: Regulatory bodies advise that, due to the risk of significant hypotension (low blood pressure) during surgical procedures, a healthcare provider or anesthesiologist may recommend adjustments. This adjustment commonly involves omitting the dose on the morning of an elective surgical procedure.


Q: What precautions are described for taking Lorista H in hot weather?

A: Precautions related to environmental conditions are documented in the official labeling. Due to the Hydrochlorothiazide component, patients are advised to limit exposure to sunlight and UV rays to minimize the risk of Non-Melanoma Skin Cancer. Additionally, the risk of low blood pressure (hypotension) is increased in patients who are volume-depleted, which can occur in hot weather.

Advertisements

How should Лориста Н be stored and disposed of?

How to Store and Dispose of Лориста Н

To ensure product stability, Лориста Н (Losartan / Hydrochlorothiazide) must be stored under specific environmental conditions defined in the official labeling. The medicine must be stored below 30 C and kept in the original container to maintain protection from both light and moisture. The tablets should not be removed from the blister packaging until immediately prior to use.

For household safety, the product is required to be kept out of the sight and reach of children.

Regarding disposal, unused or expired Лориста Н must be handled according to local requirements. Official guidelines prohibit discarding the medicine into wastewater (by flushing) or placing it in general household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Лориста Н found in:

A-Z Index: